Angiotensin receptor blockers (ARBs) for chronic heart failure (HF) at 4 weeks to 41 months*
| Comparisons | Outcomes | Number of RCTs | Weighted event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *ACE = angiotensin converting enzyme. Other abbreviations defined in glossary; weighted event rates, RRR, RRI, NNT, NNH, and CI calculated from fixed effects odds ratios and control rate in article. | |||||
| ARBs v placebo | All cause mortality | 9 | 15% v 18% | 14% (0 to 27) | 40 (21 to ∞) |
| HF hospital admission | 3 | 18% v 25% | 30% (17 to 40) | 14 (10 to 23) | |
| RRI (CI) | NNH | ||||
| ARBs v ACE inhibitors | All cause mortality | 8 | 13.4% v 12.8% | 5% (−8.8 to 22) | Not significant |
| RRR (CI) | NNT (CI) | ||||
| HF hospital admission | 3 | 15.0% v 15.6% | 4% (−11 to 17) | Not significant | |
| ARBs + ACE inhibitors v ACE inhibitors alone | All cause mortality | 7 | 22.0% v 22.6% | 2.3% (−6.1 to 10) | Not significant |
| HF hospital admission | 4 | 17% v 21% | 19% (11 to 26) | 26 (19 to 46) | |